Dr. Paul R. Fortin, MD, MPH, FRCPC holds the Tier 1 Canada Research Chair in Systemic Autoimmune Rheumatic Diseases, is Professor at Laval University, and Clinical Investigator at the CHU Research Center of Quebec – Laval University. He obtained his medical degree from Laval University and is a graduate of McGill University in rheumatology. He then obtained a Master’s in Public Health from Harvard University’s School of Public Health.

Dr. Fortin is working to better understand the bio-psycho-social impact of systemic autoimmune rheumatic diseases (SARD), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, inflammatory myositis, and antiphospholipid syndrome (APS). He is particularly interested in the development of interventions for the treatment of SLE, RA, and APS.

His methodological interests are the development and validation of diagnostic and prognostic tests, new treatments, and new ways to measure the impact of these treatments on the health status of the patient, and on the levels of activity or harm of the disease within SARDs. His other methodological interests include developing healthy lifestyle habits for people with SARD, and measuring the impact of patient knowledge.

Since 2011, Dr. Fortin has been working on the creation and establishment of a new computerized database and biobank that enables the collection of informative biospecimens and clinical data relevant to the study of SARDs. This biobank and database now has more than 13,000 biospecimens, from over 250 people, and has already contributed to translational and clinical research projects, as well as two projects funded by the Canadian Institutes of Health Research.

Dr. Fortin received the Canadian Rheumatology Association (CRA) Young Investigator Award in 1999, the Kirkland Scholar Award in 2008, and the prestigious Research Achievement Award from The Arthritis Society of Canada (2007- 2012). In 2010, he received the Lupus Ontario Hope Award for his outstanding leadership in improving the lives of people with lupus. In May 2015, he received the Jeffrey Shiroky Research Award for his clinical research achievements in rheumatology.

CHUL
2705, boulevard Laurier
T0-97
Québec, Québec
Canada G1V 4G2
361 entries « 1 of 37 »

Ugarte-Gil MF, Hanly J, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Pons-Estel BA, Alarcón GS

Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

Journal Article

Ann Rheum Dis, 2022.

Abstract | Links:

Caron P, Nguyen Van Long F, Rouleau M, Bujold E, Fortin P, Mohammadi S, Lévesque É, Breton S, Guillemette C

A liquid chromatography-mass spectrometry assay for the quantification of nucleotide sugars in human plasma and urine specimens and its clinical application

Journal Article

J Chromatogr A, 1677 , 2022.

Abstract | Links:

Barbacki A, Baron M, Wang M, Zhang Y, Stevens W, Sahhar J, Proudman S, Nikpour M, Man A,

Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling

Journal Article

Arthritis Care Res (Hoboken), 2022.

Abstract | Links:

Nevskaya T, Martin Calderon L, Baron M, Pope JE,

Health Care Utilization Is Increased In Systemic Sclerosis Patients Who Have Digital Ulcers

Journal Article

Arthritis Care Res (Hoboken), 2022.

Abstract | Links:

Muntyanu A, Ouchene L, Zhou S, Hudson M, Rezaeian M, LaChance A, Litvinov IV, Baron M, Netchiporouk E,

Geographical distribution of systemic sclerosis in Canada: An ecologic study based on the Canadian Scleroderma Research Group

Journal Article

J Am Acad Dermatol, 2022.

| Links:

Whittall-Garcia L, Goliad K, Kim M, Bonilla D, Gladman D, Urowitz M, Fortin PR, Atenafu EG, Touma Z, Wither J

Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis

Journal Article

Front Immunol, 13 , 2022.

Abstract | Links:

Michou L, Julien AS, Witteman HO, Légaré J, Ratelle L, Godbout A, Tardif J, Côté S, Boily G, Lui R, Ikic A, Trudeau H, Tremblay JL, Fortin I, Bessette L, Chetaille AL, Fortin PR

Measuring the impact of an educational intervention in rheumatoid arthritis: An open-label, randomized trial

Journal Article

Arch Rheumatol, 37 (2), 2022.

| Links:

Erton ZB, Sevim E, de Jesús GR, Cervera R, Ji L, Pengo V, Ugarte A, Andrade D, Andreoli L, Atsumi T, Fortin PR, Gerosa M, Zuo Y, Petri M, Sciascia S, Tektonidou MG, Aguirre-Zamorano MA, Branch DW, Erkan D,

Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry')

Journal Article

Lupus Sci Med, 9 (1), 2022.

Abstract | Links:

Choi MY, Clarke AE, Urowitz M, Hanly J, St-Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg D, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Buyon JP, Costenbader KH, Fritzler MJ

Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Journal Article

Ann Rheum Dis, 81 (8), 2022.

Abstract | Links:

Hasse S, Julien AS, Duchez AC, Zhao C, Boilard E, Fortin PR, Bourgoin SG

Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus

Journal Article

Lupus Sci Med, 9 (1), 2022.

Abstract | Links:

361 entries « 1 of 37 »
Signaler des ajouts ou des modifications

Active projects

  • Booster dose of mRNA SARS-CoV-2 vaccine vs non mRNA vaccine for people living with systemic autoimmune rhumatic diseases without adequate humoral response post standard mRNA vaccination, from 2021-12-01 to 2022-11-30
  • Canada research chair in Innovate Systemic Autoimmune Rheumatic Disease, from 2019-07-01 to 2026-06-30
  • CompreHensive Analysis of Mitochondria in Pathogenesis of SLE (CHAMPS), from 2021-09-01 to 2022-08-31
  • COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases / La réponse immunitaire au vaccin contre la COVID-19 chez des patients immunosupprimés en raison de maladies auto-immunes, from 2021-03-16 to 2023-03-31
  • FcgRI as a potential therapeutic target in inflammatory arthritis, from 2022-01-01 to 2025-03-31
  • Hydroxychloroquine in systemic lupus, from 2018-04-01 to 2023-03-31
  • Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-04-01 to 2025-03-31
  • Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-01-01 to 2022-12-31
  • Role of autotaxin bound to platelet-derived microparticles to development of vascular damage in arthritis., from 2015-07-01 to 2023-03-31
  • The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2- the CoVIRAL project, from 2020-04-01 to 2023-03-31
  • Understanding the pathogenesis of COVID-19, from 2020-03-01 to 2023-02-28

Recently finished projects

  • Maladies Rhumatismales Autoimmunes Systémiques (MRAS) , from 2020-12-15 to 2021-03-31
  • Mapping anti-mitochondrial antibodies in systemic lupus erythematosus, from 2019-04-01 to 2022-03-31
  • New statistical methods for cohort studies of adverse effects of medications, from 2016-07-01 to 2021-06-30
  • Profil moléculaire sanguin de patientes souffrant de lupus, from 2019-04-01 to 2021-03-31
  • Projet de recherche sur les maladies arthritiques, from 2019-12-01 to 2021-11-30
  • Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED) , from 2021-04-01 to 2022-03-31
  • Unité support du Québec: Un soutien pour la recherche axée sur le patient, from 2014-04-01 to 2022-03-31
Data provided by the Université Laval research projects registery